After receiving input from more than 80 institutions across the United States, the American Society of Health Systems Pharmacists (ASHP) and the American Pharmacists Association (APhA) developed a new medication management care transition guide.
After receiving input from more than 80 institutions across the United States, the American Society of Health Systems Pharmacists (ASHP) and the American Pharmacists Association (APhA) developed a new medication management care transition guide.
“Pharmacists’ leadership is integral to improving patient care throughout the entire medication-use process and all care settings. The programs highlighted in this report demonstrate how to improve medication adherence and reduce adverse drug events and hospital re-admissions,” said Paul W. Abramowitz, PharmD, CEO of ASHP.
The ASHP-APhA Medication Management in Care Transitions Best Practices identifies 8 programs that were distinguished as best practices because of their impacts of the care transitions model on patient care and pharmacist involvement in the transition process from inpatient to home settings. The 8 programs with the best transition programs include: Einstein Healthcare Network, Froedtert Hospital, Hennepin County Medical Center, Johns Hopkins Medicine, Mission Hospitals, Sharp HealthCare, the University of Utah Hospitals and Clinics, and the University of Pittsburgh School of Pharmacy and the University of Pittsburgh Medical Center.
The 8 organizations’ programs best demonstrate that patients benefit from the pharmacists’ medication expertise on care transitions teams. In addition, the successful transitions in these organizations depend on contributions by pharmacists, technicians, student pharmacists, supportive personnel, and other healthcare providers.
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More